跳至主要内容
临床试验/ISRCTN32422978
ISRCTN32422978已完成不适用

GEO 002: Is a reduction in urate levels the mechanism by which allopurinol improves endothelial function?

niversity of Dundee (UK)0 个研究点目标入组 30 人开始时间: 2006年1月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1. Three-month period free of hospitalisations prior to screening
  • •2. Ability to give written informed consent to participate in the study
  • •3. Diagnosis of mild to moderate chronic heart failure

排除标准

  • •1. History of drug sensitivity or allergy to probenecid or vitamin C
  • •2. Current treatment with probenecid, allopurinol, theophylline, warfarin or cytotoxic drugs (including azothiaprine or mercaptopurine)
  • •3. History of acute gout or porphyria
  • •4. Evidence of significant disease that could impair absorption, metabolism or excretion of orally-administered medication i.e.
  • •a. Renal disease (serum creatinine 180 umol/l)
  • •b. Clinically significant hepatic disease (either by lab work, i.e. alanine aminotranferease (ALT) and aspartate aminotransferase (AST) (ALT/AST > 3 times upper limit of normal, or by clinical assessment)
  • •5. Any condition with sufficient severity to impair co-operation in the study
  • •6. History of chronic alcoholism / intravenous drug abuse
  • •7. Use of another investigational drug within three months of entry into the study or within five half-lives of the investigational drug (the longer time period applying)
  • •8. Pregnancy, breast feeding or being of childbearing age and not taking oral contraceptives, all pre-menopausal women will be required to undergo a pregnancy test
  • •9. Patients on aspirin doses greater than 150 mg/day

研究者

发起方
niversity of Dundee (UK)

相似试验